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Abstract
Genomic research has rapidly expanded its scope and ambition over the past decade, promoted by 
both public and private sectors as having the potential to revolutionize clinical medicine. This 
promissory bioeconomy of genomic research and technology is generated by, and in turn 
generates, the hopes and expectations shared by investors, researchers and clinicians, patients, and 
the general public alike. Examinations of such bioeconomies have often focused on the public 
discourse, media representations, and capital investments that fuel these “regimes of hope,” but 
also crucial are the more intimate contexts of small-scale medical research, and the private hopes, 
dreams, and disappointments of those involved. Here we examine one local site of production in a 
university-based clinical research project that sought to identify novel cancer predisposition genes 
through whole genome sequencing in individuals at high risk for cancer. In-depth interviews with 
24 adults who donated samples to the study revealed an ability to shift flexibly between 
positioning themselves as research participants on the one hand, and as patients or as family 
members of patients, on the other. Similarly, interviews with members of the research team 
highlighted the dual nature of their positions as researchers and as clinicians. For both parties, this 
dual positioning shaped their investment in the project and valuing of its possible outcomes. In 
their narratives, all parties shifted between these different relational positions as they managed 
hopes and expectations for the research project. We suggest that this flexibility facilitated study 
implementation and participation in the face of potential and probable disappointment on one or 
more fronts, and acted as a key element in the resilience of this local promissory bioeconomy. We 
conclude that these multiple dimensions of relationality and positionality are inherent and essential 
in the creation of any complex economy, “bio” or otherwise.
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Introduction
Genomic research has rapidly expanded its scope and ambition over the past decade, 
promoted by both public and private sectors as holding the potential to revolutionize 
medicine through the diagnosis and treatment of disease, personalized medicine, and 
preventive care (Green et al., 2011; Guttmacher & Collins, 2005). Visions of a genomic 
future of faster and more accurate diagnoses and more targeted treatments fuel large 
investments of time, money, and emotion on the part of many stakeholders, including 
biotech companies, researchers, patients and their family members, and the general public. 
However, while there has been rapid progress in genome technologies and knowledge – for 
example, the use of sequencing for the diagnosis of rare disorders (Yang et al., 2013) – it is 
still a nascent field, as yet unable to interpret much of the information generated because of 
technological, database, and knowledge limitations (Timmermans, 2014). Yet while the 
wide-ranging promises of genomics for personalized medicine and clinical care are far from 
being realized (Evans et al., 2011; Manolio et al., 2013), belief in the potential of genomic 
medicine for health care, and the investments driven by that belief, remain largely 
undiminished (e.g., Carlson, 2013; Carrel, 2014).
Against this backdrop, particular emerging technologies have given rise to what Martin, 
Brown and Turner (2008) term “promissory bioeconomies,” in which “hope itself is being 
capitalized as the basis of commodity value” (p. 127). Research on promissory technologies 
(e.g., stem cell, cord blood banking, and gene therapy) has often focused on the role played 
by public discourse, media representations, and large-scale capital investments in fueling 
“regimes of hope” (Martin, Brown & Turner, 2008; see also Brekke & Sirnes, 2011; 
Petersen & Seear, 2011). In the context of expansionary hopes and hype, biological 
specimens (e.g., stem cells, blood, DNA), as they are technologically reformulated as 
information, come to have “biovalue,” a concept Waldby (2000, p. 33) defines as whatever 
is “generated wherever the generative and transformative productivity of living entities can 
be instrumentalized along lines which make them useful for human projects” (see also 
Waldby & Mitchell, 2006).
However, for promissory bioeconomies of this sort to function at the scale of capitalization, 
public and professional buy-in, and media hype, they rely at least at present on the creation 
and maintenance of more local networks of non-monetary exchange, trust, personal care and 
obligation that are fostered through multidimensional relationships. Novas (2006), drawing 
on his research on patient organizations and alternative forms of capitalization in the context 
of genetic diseases, emphasizes the connections between these two scales of the 
bioeconomies of genomics, and insists that we take into account the actions of the people 
whose very hopes for survival are closely bound up with the materialization of such 
promises and their relationships with the professionals whose work embodies that hope.
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Studies of the more intimate zones of activity underpinning the complex economies of 
genomic medicine have illustrated how relationships between researchers and research 
participants shape their hopes and expectations (e.g., Hallowell et al., 2010), and also drive 
investments of money, time and other types of capital. For example, Hoeyer’s (2003) long-
term research on UmanGenomics, a company with commercial rights to Sweden’s national 
biobank, provides a rich context for describing how both personal and institutional 
relationships shape practices of donation and informed consent. Hoeyer argues that the pre-
existing relationships – both personal and institutional – between donors and the nurses who 
drew samples for the biobank, were more influential in shaping donors’ decisions than were 
the informational materials provided (see also Hoeyer & Lynöe, 2006). Further, the 
expectations engendered by these pre-existing relationships both implied and were implied 
by historically and personally recognizable relational positions: most centrally, those of 
state/citizen, and nurse/patient.
In this paper, we examine a similar set of relational positions driving investments in the 
amorphous but rapidly expanding bioeconomy of whole genome sequencing (WGS). Our 
setting is a university medical center where a clinical research project recently took place 
that employed WGS and microarray analysis to identify novel cancer predisposition genes in 
families at high risk for cancer. In this project, genome sequencing was a key technology on 
which hopes and concerns drew together two groups of local investors (researcher/clinicians 
and research participant/patients) in an enterprise to build new technological presents and 
futures. Like Hoeyer and Lynoe (2006), we view relationships – both personal and 
institutional – as fundamental in shaping the expectations of both participants and 
researchers. However, we also wish to emphasize the multidimensional nature of these 
relationships in this particular setting, and the ways in which the multiple relational and 
affective positions occupied by researcher/clinicians and participant/patients influenced 
project goals and encouraged flexibility in their understanding of what constituted a 
“meaningful result.” We examine how both parties used this flexible positioning to negotiate 
uncertainty and possibility, managing expectations while fostering “reasonable” hopes.
The Study
This study was conducted as part of the larger “Whole Genomic Analysis of High Risk 
Cancer Families Study” (HRCS). The stated aim of the HRCS was to identify novel cancer 
predisposition genes through WGS and microarray analysis of patients seen in the university 
hospital cancer clinic and selected relatives suspected to have a hereditary cancer syndrome. 
Most patients had previously undergone clinically available genetic testing, but with no 
genetic mutation identified. Of the 186 participants in the larger HRCS, three-fourths were 
referred due to breast and/or ovarian cancer, about one-fifth because of colon cancer/
polyposis, and a few because of other cancers. Almost all of the participants had been seen 
clinically before study enrollment by at least one of the HRCS researchers. Participants were 
told that they would be contacted if WGS revealed the genetic cause of their condition. We 
(the authors) were invited by HRCS researchers to conduct in-depth interviews with a subset 
of these participants about their understandings and experiences related to WGS and the 
HRCS. We telephoned individuals who indicated their willingness to be contacted for the 
interview study and who were representative of the larger sample. We obtained consent 
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from the first 24 individuals who agreed to be interviewed. Table 1 depicts the demographic 
characteristics of this sample.
We conducted semi-structured telephone interviews with participants from October 2010 
through October 2011. Interview questions elicited participants’ understandings of WGS and 
the HRCS study, perceptions of the risks and benefits of participation, motivations for 
participating, expectations for return of results and other study outcomes, and overall 
evaluations of their experience with the study. We also interviewed the three HRCS 
researchers who had direct contact with the participants (two clinical geneticists and the 
genetic counselor who served as the HRCS study coordinator) about their overall goals, 
hopes, and expectations for WGS and the study; perceptions of possible benefits and risks; 
and how they perceived their relationships with participants. Interviews averaged one hour 
and were digitally recorded and transcribed. The interview study and the HRCS were 
approved by the university IRB.
For this study, analysis of interview data focused particularly on how researchers and 
participants viewed the value and nature of their investment in the HRCS. We reviewed each 
transcript to gain a holistic sense of the range and dimensions of the meanings of the 
responses. We then generated a coding scheme through an iterative process that is standard 
for content analysis (Miles, Huberman, & Saldaña, 2013; Patton, 2002). Codes were based 
on the specific topics elicited by interview questions (e.g., understandings, hopes, 
expectations, risks, benefits, goals of WGS/HRCS). The first author used Atlas.ti to code the 
transcripts for these topics. Responses related to each code (e.g., benefits of study 
participation) were collated for each interviewee, summarized, and recorded in a data 
display matrix to aid in systematic comparison (Miles et al., 2013). The authors’ analysis of 
these responses followed procedures derived from abductive and grounded theory (Charmaz, 
2006; Tavory & Timmermans, 2014; Timmermans & Tavory, 2007). This led to findings 
related to each specific topic, but also to an overarching interpretation of the importance of 
flexible positionality in local productions of a promissory bioeconomy. In this account, we 
first describe the histories that participants and researchers brought to the study, including 
the relationships between members of each group, and show how these histories made 
possible a flexible positioning that is not always a feature of researcher/participant relations. 
Second, we examine the variety of types of investments made by each group, defining 
investment as including not only monetary or material resources, but also the time, social 
capital, and emotional labor contributed. Third, we discuss the variety of types of biovalue 
these investments helped to create, highlighting in particular the value that participants and 
researchers placed on genomic information as a gift, in addition to its potential future 
valuation as a commodity.
Flexible Positionality
Anthropologists and other scholars of human interaction have long emphasized the 
importance of attending to the various roles people adopt in different situations, stressing the 
dynamic nature of identifications as particular types of people and as members of specific 
collectives (Castells, 1997; Heath, Rapp, & Taussig, 2004; Holland et al., 1998). Whether 
referred to as “roles,” “identities,” or “positions,” what is important is not simply the 
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multiplicity of such positions available, but the multiplicity of relationships they imply. In 
this analysis, we point to the salience for both researchers and participants of their different 
positions within the context of the HRCS. For participants, both the position of patient and 
that of family member were of high importance, along with that of research participant; 
while for researchers, the position of clinician (physician or genetic counselor) also figured 
heavily in structuring their experience of, and orientation to, the study.
Integral to participants’ experiences in the HRCS was that the vast majority had at some 
point in their lives been diagnosed with cancer or precancerous symptoms, and all had a 
family history of cancer. At the time of the study, most participants had been treated for 
cancer, some were still actively undergoing treatment, and almost all were vigilantly 
following screening protocols. Their experiences as cancer or “pre-cancer” patients 
influenced their perceptions of the HRCS, its goals, and potential benefits. They were 
motivated to join the study to see if WGS could reveal the molecular cause of their cancer.
Even though the HRCS team informed them that the odds of finding the genetic cause of 
their cancer was low, participants viewed the research as a natural continuation of their 
search for answers and saw WGS as being little different from other testing except that, as 
part of a research study, it was free. For example, Laura (all names are pseudonyms), who 
had atypical breast cells and a cousin with breast cancer, recalled being very excited to join 
the study so she could continue her search for the cause of her family’s breast cancer: “I had 
been tested, and my cousin had been tested, and it appeared that we did not have BRCA1, 
BRCA2, and it looked like our research [i.e., our search for a diagnosis] would pretty much 
end because of the financial responsibility that it would personally be if I did continue.”
Laura, like others in the study, did not draw clear lines between her prior clinical experience 
and the research context of the HRCS in her search for diagnostic answers. Allison also 
described her entry into the study as a logical extension of her clinical experience:
I remember [the study coordinator] telling me at the time that they had come up 
with maybe some kind of new testing, newer than when I had first come to [the 
university] because in the beginning they couldn’t definitely diagnose me with a 
polyposis, but I was hoping that with this they could come even closer.
Participants’ positions as family members were also motivating, as they wanted to find the 
cause of their past, present, and imagined future relatives’ cancers. Many drew on 
experiences of their own cancer or those of their parents or siblings to describe the ways 
they envisioned their relatives potentially benefiting from the study. Angela, who had 
survived breast cancer, spoke about the difficult choice she had been contemplating in 
regard to a prophylactic hysterectomy, and linked this to the decisions her daughters might 
someday need to make. “Being part of the study,” Angela explained, “has been a real 
opportunity for me to do what I can to empower myself to learn things that I can use in my 
own life and pass along to both my daughters as far as ways that they should live and 
choices that they should make to decrease their chances of getting it.” Angela also noted that 
her daughters were both willing participants in the HRCS because, as she described, they 
had “seen what I’ve been through. They’ve seen what I went through when my mom had it 
twice, and they’ve been there as far as seeing what cancer can do to a family.”
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Participants’ willingness to join the HRCS was enhanced by their pre-existing clinical 
relationships with one or more members of the research team and the university medical 
system of which they or their relatives were a part. They expressed personal trust in the 
research team as well as a high degree of confidence in the university as an institution. Lucy, 
who had a personal and family history of colon cancer, said, “I trust the folks there. They’ve 
always been straight with me and telling me just like it is.” Similarly, Jennifer, who had 
been treated for breast cancer by the HRCS researchers in their role as clinicians, described 
how this previous relationship influenced her to join the study:
When she [the study coordinator] called me, it was someone – I’ve met her face to 
face. So I had a relationship. It wasn’t like some stranger calling me out of the clear 
blue saying, “Would you be interested in being in this study?”
In some cases, participants’ feelings toward both the university and the HRCS researchers 
went beyond trust, toward something akin to obligation as Jennifer expressed: “They were 
so wonderful to me when I was a patient…I would have done anything to have helped 
them.” By “obligation,” we are not implying that the participants felt pressured or coerced to 
participate in the study. Indeed, they viewed the HRCS as a fortuitous opportunity, and they 
perceived their participation in part as a chance to give back to the clinicians who had 
helped them and whose research they identified with at a personal level. They had a sense of 
being a “research participant” in a real and active way, in large part because of their prior 
and present experiences as patients receiving clinical care. Jennifer, like other participants, 
spoke as if she were a member of the research team rather than a passive subject, referring 
not to “they” the researchers, but to “we” the team of people trying to help the next 
generation. Martina, who had a history of colon cancer, explained, “We’re kind of all in this 
together trying to figure this out.”
Researchers’ perspectives on their hopes for, and obligations to, participants were similarly 
filtered by their previous clinical interactions. Ms. Roberts, the genetic counselor and HRCS 
study coordinator, spoke at length about her ongoing relationships with the participants. She 
knew many of them well and had watched them struggle emotionally, blaming themselves 
for their disease and pondering what they might have done to cause it. She believed that 
finding the genetic cause would go a long way toward alleviating this emotional burden:
Whatever they’ve done in their life they’ve sort of blamed, or they’ve racked their 
brain trying to figure out what it was. So I think having another cause that they 
know they had no control over, or very little control over, is helpful in getting that 
answer for them.
Dr. Charles, the principal investigator of the HRCS, also talked about the effects of 
preexisting clinical relationships on both his and participants’ approaches to the study. 
Although he stressed he did not know most participants like their general practitioner would, 
he described how being there with them at “critical junctures” in their lives led to a deep, if 
circumscribed, awareness of their travails, and like Ms. Roberts, described in some detail the 
emotional struggles he saw participants deal with regarding their genetic legacy.
All three HRCS researchers expressed a strong desire to provide diagnostic answers for the 
participants and their families. Although they were sensitive to their obligations as 
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researchers – for example, expressing deep concern that participants understood the study, 
its risks and benefits, and the unlikeliness of finding the genetic cause of their condition – 
they nonetheless appeared to think of the participants first and foremost as patients in search 
of answers, and they reckoned the project’s success in terms of providing a personal answer 
as much as in more scientific terms of finding novel disease-causing variants. This is 
apparent in Dr. Charles’ explanation of how the study began:
We’ve been keeping track of patients now for seventeen years who we have been 
seeing in the cancer genetics clinic, and we will have patients…whom we are 
unable to give an answer…So we’ve been keeping track of those patients in a 
database for a long time with the hope that someday we’d be able to address it.
In the interviews, all parties shifted between different relational positions as they managed 
their hopes and expectations for the research. These positions also shaped their investments 
in the project and their valuing of its possible outcomes – all key elements in the creation of 
this local promissory economy.
Investing in hope
Our conceptualization and analysis of researchers’ and participants’ views of their 
investment in the HRCS include both monetary and material contributions as well as the 
time, social capital, and emotional labor expended. . Participants viewed giving a blood 
sample as a simple investment that could reap potentially large rewards. When asked the 
most important thing that people should consider when deciding to participate, Laura 
replied:
How very easy it is for the people giving the blood, giving the samples. It’s just a 
venipuncture really and a little paperwork to be involved. It’s no invasion. It 
doesn’t upset your life at all, and yet you might be able to get back great, wonderful 
information for your family.
Participants did not experience the basic requirements of study participation as greatly 
onerous; nor did they expound on the other types of labor in which many of them engaged, 
such as time spent recruiting relatives to join the study. Researchers had communicated that 
the participation of multiple relatives was essential to the task of identifying cancer risk 
genes, and participants expended effort and utilized their own social capital within their 
families to recruit them. Those who ended up recruiting numerous relatives expressed pride 
and satisfaction in doing so, while those who were unable to persuade relatives to participate 
expressed deep disappointment.
The researchers also spoke about what they viewed as investments on the part of 
participants, again framing these in the context of pre-existing clinical relationships. Dr. 
Charles noted that the clinician-patient relationship set the stage for obligations and 
expectations on both sides that differed from what he described as the more “contractual” 
relationship found in purely research studies where such relationships mostly do not exist. 
He explained:
I think when you start taking care of somebody, and you’ve touched them, literally 
touched them … it definitely changes that relationship, and it’s less contractual and 
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more intimate and more serious with expectations on both sides. They expect you 
to help them, and you expect – what do you expect from them that you don’t expect 
from a (research) subject? I guess an investment, and I guess there’s an expectation 
of trust.
Ms. Roberts also talked about her strong sense of obligation to the HRCS participants, 
especially to those who had demonstrated their investment by convincing relatives to join 
the study:
I want to find something in all the families, but there are some families that you do 
get more attached to just because they’ve gotten all of these relatives to participate, 
and they have so much invested. … You’d really like to be able to help them just 
because you know they are so invested in it.
We also include as forms of investment participants’ willingness to take what some 
perceived as significant risks, including offering up their own biological material for 
research (see also Waldby, 2002). Most participants were unconcerned with the risks of the 
study, such as privacy issues related to genetic information. A few, however, viewed their 
donation of blood as a significant act with some potential harm involved. For example, 
Candice, who had a family history of breast cancer, worried that information uncovered 
during the study might affect her health insurance, and Lucy raised the possibility that 
genetic testing could result in unpleasant surprises regarding paternity or adoption. Though 
these and other possible risks were acknowledged, participants were motivated to join the 
HRCS to find an answer for themselves and their families and to contribute to the scientific 
enterprise. These potential benefits justified their investment and outweighed any concerns.
The researchers had also invested large amounts of time, money, emotion, and social and 
professional capital in the study, although Dr. Charles noted that this was typical for all 
research. As mentioned above, they had collected, over more than a decade, the names of 
potential participants, with the hope that they might one day be able to provide answers for 
them. Dr. Charles, the lead researcher, noted in an interview that he had “a grant that I got a 
few years ago that still had some money on it,” which he was able to direct toward the 
HRCS. He and other researchers, he explained, had attempted a similar project several years 
earlier, but the state of the technology had presented a barrier, so he had held onto the grant 
money in anticipation of a better opportunity. The HRCS study then represented the 
culmination of that hope, and the researchers’ professional identities were very much bound 
up in conducting the project. Dr. Charles also acknowledged certain risks to himself and the 
research team. Although he rated it as unlikely, he noted that if there were to be a security 
breach (as had recently happened elsewhere within the university), he personally could be 
held responsible by the administration.
(Bio)value: information, results, and knowledge
These kinds of investments by both researchers and participants led to a form of biovalue 
central to both parties: “information.” In elaborating her definition of biovalue as a “yield of 
vitality produced by the biotechnical reformulation of living processes,” Waldby (2002, p. 
310) noted that both use value and exchange value are pertinent to its valuation. Where 
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classical Marxist theory defines exchange value strictly as a commodity price, we, like 
Waldby, emphasize that even in bioeconomies embedded in capitalist systems, biovalue is 
exchanged not solely as a commodity (although often, of course, it is), but also as a gift as 
we discuss below.
Participants spoke of “information” both as something that they first gave to the researchers 
through their DNA sequence data and family history, and then as something that researchers 
returned back to them in the form of diagnostic results, which participants in turn could 
share with their families. Although most viewed a diagnostic result as highly valuable and 
desirable, the vast majority did not expect clinical benefits for themselves. Rather, they 
anticipated being able to pass this information to family members, for whom clinical utility 
might be more likely in terms of preventive strategies or future therapies. For example, 
Diane, who shared with her family a history of polyposis, said: “If something did show up 
… it would be something that I could share with [family members] as sort of a warning to 
them to stay on top of this, and make sure that they don’t miss their colonoscopies and/or to 
get started taking them earlier.”
Participants often talked about WGS results as a gift that they could bestow upon their 
families. Laura understood the HRCS as “probably giving your family – the family in the 
future, your children, your grandchildren – power with the knowledge that can come from 
this.” Knowledge, then, was a form of information created by the researchers through the 
analysis of many participants’ information, but could also be re-converted into results 
specific to one individual or family. For example, Luke, who had a family history of polyps, 
said that his main motivation for study participation was “furthering human knowledge.” 
However, he also wanted to learn “information” about himself.
Researchers’ valuing of the study largely paralleled these distinctions. Dr. Charles described 
two goals for the HRCS:
I think there are two very related goals … on one hand the discovery of novel genes 
that are involved in cancer pre-disposition and causation. …The other major goal of 
the study is to give some patients … concrete tangible insight into what it was or 
what it is that is causing the cancer pre-disposition in their family so that their 
family members could take immediate and useful measures for prevention.
This explanation provides food for thought in relation to both types of valued information. 
Dr. Charles advances the possibility of providing personal genetic results, or “answers” to 
some participants, not as a potential bonus – a welcome side effect of a study oriented 
toward the production of generalizable knowledge – but as an equally important goal. Recall 
that participants were “collected” over years into a database of patients for whom Dr. 
Charles and Ms. Roberts wished to provide “answers.” Importantly, the researchers 
explained that their ability to provide these answers was not premised solely on success in 
generating new knowledge (i.e., gene discovery). Results could also come about as a 
consequence of sequencing participants’ genomes and finding rare variants known to be 
associated with cancer risk but not detectable through currently available clinical testing. 
Indeed, as the study progressed, at least one family’s cancer was found to be linked to one of 
these rare variants.
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Successfully identifying the genetic variant causing a person’s cancer may not provide a 
medically actionable course, calling into question this information’s “use value.” However, 
the value of a genetic result lies not only in its clinical utility, but also in its personal utility. 
Ms. Roberts strongly felt that this information would be of high personal value for the 
participants: they would benefit from getting an answer so that they could “put a name on it 
and in some cases from being able to identify a cause beyond their control, for which they 
could stop blaming themselves”; and they could learn more about the risks for relatives and 
share this with them – a primary motivation for joining the study.
This notion of family benefit poses a major challenge to the framing of the individual patient 
as an autonomous individual, and therefore to individualistic understandings of “benefit” 
from research participation. The HRCS was unlikely to provide “medically actionable” 
results to individual participants, but neither researchers nor participants themselves 
understood the individual to be the most relevant unit. For both researchers and participants, 
the family was the collective patient, and information gleaned from WGS had use value for 
this collective. Dr. Charles said simply, “The family is your patient.” Dr. Hamlet noted that 
it did not matter whether or not a given family member had actually given a sample, saying, 
“Everyone in the family is kind of in the same boat, whether they’re in the study or not.”
For most participants, discussions of family benefit also served as a discursive bridge 
between the notions of “results” and of “knowledge.” They acknowledged that while they 
hoped their own families would benefit through getting diagnostic results from WGS, they 
did not necessarily expect this to happen. Participants managed their expectations in this 
regard by a discursive blurring of “my family” with “someone’s family,” and by 
emphasizing their positioning as participants in a research study rather than as patients or as 
family members. As Giselle stated, “There are many, many, many families out there just like 
ours. … It does benefit my family, but it also benefits the people – women – across the 
world.” Frank, whose daughters had breast cancer, framed his hopes for the study 
metaphorically: “I hope that I am one little [grain of] sand in the big building that the people 
are building that finds ways to prevent cancer or treat cancer.”
While a few participants spoke broadly of the aims of the HRCS as “fighting for a cure,” 
they viewed the value generated by the study more specifically. Most identified improved 
screening techniques as a realistic near-term goal, highlighting prevention rather than 
treatment. Participants with a family history of breast cancer and past experiences with 
genetic testing for BRCA1/2, in particular, spoke of their hopes for the study to lead to new 
tests that would identify novel cancer-causing variants. Jennifer, who had several relatives 
diagnosed with breast cancer, explained:
If it’s successful, it may be like BRCA1 and 2. People can be tested to know–have 
some information ahead of time to make a decision: “Do I have a prophylactic 
mastectomy? Is there some kind of treatment that can be done instead of waiting 
around to develop breast cancer?”
These hopes for better surveillance also surfaced in the interviews with colon cancer 
patients, who did not have as much experience with genetic testing but had long histories of 
screening.
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One major difference between participants’ and researchers’ understandings of the societal 
value of the study was temporal in nature. Whereas participants talked about the research as 
leading more or less directly to screening technologies with immediate clinical utility – if 
not for them, then for their family or others in society – researchers focused more on 
medium and long-term research outcomes, describing the incremental gains in knowledge 
that could be obtained through the application of other researchers’ ideas and technological 
expertise to their findings. Dr. Charles emphasized that the goal of gene discovery was, in 
his view, “far, far down the pike.” He also sounded a cautionary note in regard to the idea of 
“benefit”:
I would say in all likelihood, like most research, the benefit will be very tiny; it’ll 
be very incremental, and it will be very much in the long-term towards people who 
may have benefitted gradually from better diagnostics and better treatments.
In a second contrast, while participants envisioned benefits broadly as applying to “all 
women” or “all people with cancer,” researchers were much more cautious in identifying 
beneficiary populations or hyping the magnitude of the possible outcomes. Unlike 
participants, who sometimes conflated this study with BRCA testing and often drew on the 
BRCA example as a means to frame the potential value of the knowledge produced within 
the study, researchers used it as a point of contrast, something their own study could not 
achieve. Dr. Hamlet explained:
The mythical BRCA3 would be the best outcome, but of course that won’t happen 
because enough has been done upon hereditary breast and ovarian cancer that we 
pretty much know by now that BRCA1 and 2 account for the majority of families 
with hereditary breast and ovarian cancer, and each individual gene accounts for a 
smaller and smaller slice of the pie. And so we’re probably at the point where a 
new gene that we discovered might account for the hereditary–the familial breast 
cancer in one percent of families or two percent of families, and we’d be lucky if 
we found one that was anything more than two or three percent.
Researchers’ emphasis on the value of the study, then, was on the long and sometimes 
meandering road from blood sample to result to treatment, and the complexity of trying to 
solve such a multifaceted problem as “cancer.” They did not envision this enterprise as one 
big project as did some participants, but stressed the many partial connections and 
contingent pathways of discovery that could at times lead nowhere. The knowledge 
produced by the HRCS would need to circulate far and wide to be materialized as clinical 
applications that would result in Waldby’s “yield of vitality” – a longer life or better quality 
of life for someone else.
Researchers also acknowledged the (non-monetary) exchange value inherent in this 
knowledge. Dr. Charles candidly discussed the nature of academic research and the many 
kinds of prestige and acknowledgement that scientists pursue:
Everybody has conflict of interest that isn’t financial. You want a promotion. You 
want to make full professor, and you want to publish. You want to see your name 
in print. You want people to talk about your research. You know we all have these 
venal motivations that prompt us. … So that’s absolutely a motivation. The reason I 
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think it gets talked about less is, besides the fact that it flies in the face of the 
altruistic scientist who’s trying to help humanity, is that it’s also hard to quantify. 
It’s easy to quantify conflicts of interest or just interests that are monetary. It’s very 
hard to quantify: “I want promotion. I want my friends to think I’m a success.”
Despite Dr. Charles’ candid acknowledgement of the cultural and social capital that might 
accrue to a successful researcher, the overall emphasis in interviews with both researchers 
and participants was not on their individual prospects for “benefit” through the use of the 
information generated, but rather the need for information to circulate, and ideally, to 
circulate freely – in order to be of benefit. The researchers in particular stressed their strong 
opposition to financially benefiting from the HRCS (e.g., by patenting any genetic 
discoveries), while most of the participants seemed unaware of the huge commercial 
interests in the genetics industry. In fact, both researchers and participants spoke of the 
information the study would produce as a type of gift – something of value that could be 
given to those they cared about. Researcher/clinicians hoped to be able to give “answers” to 
people they knew and had cared for as patients. Participants hoped to be able to give these 
“answers” in turn to members of their family, including those who had not yet been born. 
Both parties hoped that the information they generated locally would circulate through the 
world of science to create “knowledge” that would benefit people around the world. While 
the research team, however, was well aware of the potential for private actors to attempt to 
control and capitalize on this circulation, research participants did not demonstrate to any 
significant degree an awareness that the gifts they gave freely might be transmuted into 
commodities for which they, their families, or “someone else’s family in the future” would 
have to pay. The vague and somewhat naïve nature of participants’ understandings of the 
processes by which information circulates at varying degrees of abstraction to become 
scientific knowledge illuminates the extent to which trusting relationships between 
researchers and participants shape decisions around participation. In the context of the 
HRCS, we do not believe this trust to have been misplaced; nonetheless, the broader 
implications are concerning, as we discuss further below.
Discussion
Genomic research and the creation of promissory bioeconomies around it involve multiple 
categories of investors in complex webs of interdependence that extend far beyond the 
obligations outlined in study protocols and consent forms. The HRCS provides an example 
of the development of a local promissory economy that emerged out of the flexible 
positionalities of researchers and participants and their understandings of one another’s 
hopes and expectations for the study, which in turn motivated their investments of time, 
emotion, social capital, trust, and resources.
One possible structure for such a bioeconomy is found in many biobank projects. As 
elaborated by Tutton (2004), these projects are characterized by a type of gift economy, or at 
least a discourse of giving, that guides approaches to sample donation, while the valuation 
through exchange of information extracted from these samples rests on a far more 
commercialized economy (Busby, 2006; Hoeyer, 2003; Tutton, 2004). Such projects call 
attention to the ways in which genetic research participants may envision an abstract and 
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expansive “good” that science will produce from the tissues and resulting information they 
have offered—a vision that genetic researchers may be disinclined (because of narrower 
commercial interests) or simply unable to fulfill (Hoeyer & Lynoe 2006; Michie et al. 2011; 
Reddy 2007). In the context of the HRCS, however, the separation of “tissue” from 
“information” economies was not so strict nor the reciprocity so limited. Both “results” and 
“knowledge” were prized as study outcomes by participants and researchers alike, not for 
their commercial exchange value nor for individual use, but as gifts that needed to circulate 
in order to be of value. In this sense the HRCS researchers – though likely not the 
participants – differ markedly from those involved in more commercialized research 
projects. In the latter cases, some bioethicists have expressed concerns that the “gift” 
motivations of research participants implicitly demand an ethical reciprocation that may not 
be forthcoming (Hoeyer, 2003; Tobin et al., 2012).
Our findings also indicate that in large part the distinction between “research” and “clinical 
care” is one that is not fixed or even separable into distinct spheres of practice in studies 
such as the HRCS that enroll patients with a goal of discovering information potentially of 
both personal and scientific value (e.g., Berg et al., 2013; Foreman, Lee, & Evans, 2013). 
This distinction is instead flexibly applied to manage expectations while cautiously fostering 
the hopes needed to promote research participation. In accord with Easter et al. (2006), we 
suggest that the combination of research that includes forms of clinical practice (e.g., return 
of results, genetic counseling, referrals) under some circumstances functions to temper 
unrealistic expectations on the part of researchers and participants alike, and to impart an 
important human dimension to technological hopes for the future. As such, this study adds 
to literature on the implications of returning individual research results for the research/
clinical practice boundary (Miller et al., 2008), and on the ambiguity of this boundary and 
the ethical responsibilities this ambiguity entails (Burke et al., 2014; Pullman & 
Hodgkinson, 2006).
In the HRCS the different positions and relationships occupied by researchers and 
participants gave each party insight into the different facets of the study. Each had a better 
understanding of what a meaningful result might look like from the other’s perspective than 
they might have had without these multiple dimensions of relation; and this insight helped 
each to conceptualize and invest in more than one type of value as a potential outcome of the 
study. Participants’ positioning as research subjects, patients, and family members gave 
them a range of perspectives on the cancer research enterprise. Their pre-existing 
relationships with the researchers and the university health system also allowed them to 
position themselves as “part of the team” in a substantive way. While they understood their 
participation in part as a continuation of prior clinical testing, they were also invested in the 
production of more generalized knowledge about cancer in hopes that this knowledge would 
benefit future generations of their own families. We suggest that participants’ flexible 
positions both limited their dependence on a therapeutic misconception that the research 
would benefit them directly and expanded their concept of therapeutic benefit well beyond 
their individual health outcomes (see Appelbaum et al., 1982; Appelbaum et al., 1987; 
Kimmelman, 2007). Similarly, researchers’ expectations of the value that personal results 
would have for participants were also filtered through their prior knowledge of these 
participants as patients: of their medical histories of surveillance and treatment, and of their 
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often equally long histories of searching for answers both for themselves and for their 
families. These intimate understandings and their past relationships as caring clinicians to 
the participants clearly shaped their hopes for what they might realistically be able to do for 
people, beyond the hope of “scientific progress.”
Both participants and researchers positioned the family as the key unit of benefit. Most 
participants did not expect to benefit personally from the HRCS, but they were motivated to 
join the study in hopes that it could at some point provide information of use to their own, or 
to “someone’s family.” Researchers also viewed the family as immediate beneficiaries if 
diagnostic results were found, and as long-term potential beneficiaries of genomic 
knowledge. This emphasis on family further calls into question the notion of the 
autonomous patient/participant in genomic research, and the implications of that for consent 
and return of results--issues at the forefront of much debate in genomic research (e.g., 
Beskow & Burke, 2010; McGuire, Caulfield, & Cho, 2008; Wolf, 2012).
In interviews, respondents easily shifted between these positional identifications in the 
course of framing and managing their own hopes and expectations for the study. We suggest 
that this flexibility facilitated their participation in the face of potential and probable 
disappointment on one or more fronts, and is a key element in the resilience of “bio-
economies” more generally despite experiences of failure. Rather than viewing multiple 
dimensions of relationality and positionality as inherently problematic, we view this 
multiplicity as simply inherent and essential in the creation of any complex economy, “bio” 
or otherwise. Similarly, the broad and multifaceted nature of “investment” by flexibly 
positioned researchers and participants in this study offers an enriched understanding of the 
biovalue that these investments generate, both in the present and in an envisioned and 
hoped-for future. While based on a small, relatively homogeneous sample, our findings are 
suggestive and signal a need for greater understanding of the relational processes through 
which the possibility of obtaining clinically meaningful information from genome 
sequencing is constituted, interpreted, and situated by researchers/clinicians and participants/
patients within the context of other overlapping hopes, fears, expectations, and obligations.
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Small-scale research studies are an underexplored dimension of genomic 
bioeconomies
Boundaries between research and clinical care practices are not fixed or separable
Managing expectations while fostering hope is essential to bioeconomies’ resilience
“Information” is a key form of genomic biovalue, both as gift and commodity
Researcher-participant relationships shape the biovalue of genomic information
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Table 1
Characteristics of Study Sample (n=24)
Characteristics Number
Gender
  Female 21
  Male 3
Years of Age
  25–44 4
  45–54 7
  55–64 8
  65–74 5
Study Indication
  Breast/Ovarian 15
  Colon/Polyps 9
Relationship
  Proband 16
  Relative 8
Years of Education
  Less that high school 1
  High school diploma 0
  Some college 9
  College degree 9
  Advanced degree 5
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